Top

Published in:

01-08-2009 | Letter

Robotic D2 surgery for gastric cancer

Authors: H. Demetetriades, G. N. Marakis, D. Ziogas, I. Kanellos

Published in: Surgical Endoscopy | Issue 8/2009

Excerpt

Over the last few years, rapidly increasing use of robotic-assisted surgery has being occurring for the treatment of gastrointestinal, urological, and gynecological malignancies. There is growing evidence highlighting the benefits of robotic surgery in management of these tumors. The advantages of the robotic system include three-dimensional vision, tremor reduction, seven degrees of intra-abdominal articulation, and motion scaling. Recent reviews suggest the feasibility and safety of robotic approaches in a variety of radical oncological surgical procedures [1, 2] that in selected rectal cancer cases might improve also overall survival [3]. …

Anderson C, Hellan M, Kernstine K, Ellenhorn J, Lai L, Trisal V, Pigazzi A (2007) Robotic surgery for gastrointestinal malignancies. Int J Med Robot 3(4):297–300PubMed

Ramirez PT, Soliman PT, Schmeler KM, dos Reis R, Frumovitz M (2008) Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer. Gynecol Oncol 110(3 Suppl 2):S21–S24PubMedCrossRef

Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406PubMedCrossRef

McLeod R (2008) Long-term results of laparoscopic-assisted colectomy are comparable to results after open colectomy. Ann Surg 248(1):8–9PubMedCrossRef

Patriti A, Ceccarelli G, Bellochi R, Bartoli A, Spaziani A, Di Zitti L, Casciola L (2008) Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surg Endosc, Sep 24 [Epub ahead of print]

Sasako M, Sano T, Yamamoto S, For Japan Clinical Oncology Group et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359(5):453–462PubMedCrossRef

Liakakos T, Roukos DH (2008) More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960PubMedCrossRef

Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830PubMedCrossRef

Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129PubMedCrossRef

10.

Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMed

11.

Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221PubMedCrossRef

12.

Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939PubMedCrossRef

13.

Punglia RS, Morrow M, Winer EP et al (2007) Local therapy and survival in breast cancer. N Engl J Med 356:2399–2405PubMedCrossRef

14.

Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRef

15.

Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRef

16.

Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRef

17.

Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283–291PubMedCrossRef

18.

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715PubMedCrossRef

19.

Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312PubMedCrossRef

20.

Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4(10):578–590PubMedCrossRef

21.

Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(15):1555–1556 author reply 1556PubMedCrossRef

22.

Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33PubMedCrossRef

23.

Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMed

24.

Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034PubMedCrossRef

25.

Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597PubMedCrossRef

26.

Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361PubMedCrossRef

27.

Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197 author reply 198PubMedCrossRef

28.

Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636 author reply 1636PubMed

29.

Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362–1363PubMedCrossRef

30.

Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798PubMedCrossRef

31.

Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773PubMedCrossRef

32.

Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392PubMedCrossRef

33.

Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, casual networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221PubMedCrossRef

Title: Robotic D2 surgery for gastric cancer
Authors: H. Demetetriades
G. N. Marakis
D. Ziogas
I. Kanellos
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 8/2009
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-009-0496-1

At a glance: The STEP trials

Springer Medicine

Robotic D2 surgery for gastric cancer

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2009

Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection

Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results

Impact of surgical peritoneal environment on postoperative tumor growth and dissemination in a preimplanted tumor model

Laparoscopic completely extraperitoneal repair of inguinal hernia in children: a single-institute experience with 1,257 repairs compared with cut-down herniorrhaphy

Laparoscopically assisted ileocolectomy in patients with Crohn’s disease: a study of 50 consecutive patients

Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study